However, when combined DDU at PSV 290 cm/sec with VP ratio 0.2, it provided similar sensitivity and specificity to UDT at 750 ml/min. KASUGA HIROTAKE1, TAKAHASHI RYO1, KIMURA KEIKO1, MATSUBARA CHIEKO1, KAWASHIMA KIYOHITO1, ITO YASUHIKO2, MATSUO SEIICHI2, KAWAHARA HIROHISA1 1Nagoya Kyoritsu Hospital; 2Nagoya University Graduate School of Medicine Introduction: Erythropoiesis stimulating agents (ESA) are standard therapy for anemia in maintenance Hemodialysis (HD) patients. Recently, two type Tanespimycin datasheet long acting ESA, Darbepoetin alfa (DA) and Epoetin beta pegol (C.E.R.A.), have been used for ESA therapy

in Japanese HD patients. These ESAs have longer half life time than that of Epoetin (EPO), so-called short acting ESA, therefore the frequency of ESA injection is fewer than EPO. However, comparison with efficacy of DA and CERA is not studied enough

in Japan. In this study, we compared Dabrafenib clinical trial the difference of efficacy between DA and C.E.R.A. in Japanese HD patients. Methods: 161 maintenance HD outpatients who received EPO therapy were divided into two groups, and switched EPO to DA (DA group, n = 83) or to C.E.R.A. (CERA group, n = 78). Patients of DA group received DA injection once every week, and patients of C.E.R.A. group received C.E.R.A. injection once every month. These therapies were continued for 6 months or more, and compared Hb levels in two groups. Results: Patients’ characteristics ADAM7 of two groups were comparable. Hb levels before

ESA switching and at 6 months after switching were 10.8 ± 1.0 g/dL and 11.0 ± 1.1 g/dL in DA group, and 10.8 ± 1.0 g/dL and 10.8 ± 1.1 g/dL in CERA group, respectively. Ferritin levels and trasferrin saturation (TSAT) of DA group before and 6 months after switching were 95 ± 100.4 ng/mL, 22.3 ± 8.5% and 103 ± 124.8 ng/mL, 23.7 ± 10.1%, respectively. On the other hand, those of CERA group were 98.1 ± 105.9 ng/mL, 21.8 ± 9.0% and 106.3 ± 92.1 ng/mL, 27.8 ± 11.2%, respectively. TSAT of CERA group was significantly elevated at the end of the study (p < 0.00005). Conclusion: In this study’s setting, DA and C.E.R.A were similarly useful for anemia therapy in Japanese HD patients. But, C.E.R.A may induce storage of iron for erythropoiesis compared to DA. LI CHEN-HAO1,2, HUANG CHEN-SEN1, HUS TAN-YUN2, WANG SHI-PEI2, WU YEA-FANG2, TSAI JEN-PI2 1Department of Nephrology, Buddhist Dalin Tzu Chi General Hospital; 2Department of Nursing, Buddhist Dalin Tzu Chi Hospital, Taiwan Introduction: Peripheral arterial occlusive disease (PAOD) is one of the systemic manifestation of atherosclerosis. The prevalence rate of PAOD among patients on hemodialysis ranged from 23% to 50%. In addition to the traditional factors, nontraditional (uremic) factors of atherosclerosis play an important role. Therefore, we tried to identify risk factors of PAOD in the hemodialysis patients.